image description

Tag: Genentech

Obinutuzumab Showed Significantly Positive Results in Published Phase III Lupus Nephritis Study

Exciting breaking news: A paper published in the highly prestigious journal New England Journal of Medicine and presented at the World Congress of Nephrology reported that results of the Phase III REGENCY trial found that among people with active lupus nephritis, Gazyva® (obinutuzumab) plus standard therapy demonstrated statistically significant and clinically meaningful improvement in the […] Read More

LRA Forum for Discovery Showcases Cutting-Edge Lupus Research

The Lupus Research Alliance (LRA) hosted its highly anticipated annual scientific conference, Forum for Discovery (FFD), November 11-13 in New York City. A hallmark event for the lupus research community, FFD brings together LRA-funded investigators from across the globe to discuss the latest breakthroughs of their LRA-funded projects. Serving as a crucial platform for fostering […] Read More

Gazyva® Shows Positive Results in Phase 3 Lupus Nephritis Trial

The Lupus Research Alliance (LRA) and clinical research affiliate Lupus Therapeutics (LT) are excited to share positive news of the Phase 3 REGENCY clinical trial showing benefits of Gazyva® (obinutuzumab) in treating people with active lupus nephritis (inflammation of the kidney associated with lupus). In development as a potential treatment for lupus nephritis, Gazyva is approved in […] Read More

Multi-ethnic Study Identifies New Genetic Markers for Lupus

Scientists from an international consortium have identified a large number of new genetic markers that predispose individuals to lupus. The study is published in the July 17 issue of the journal Nature Communications and was led by researchers at Wake Forest Baptist Medical Center, Oklahoma Medical Research Foundation, King’s College of London and Genentech Inc. Autoimmune diseases […] Read More